Reports Q4 revenue $878M, consensus $860.76M. “In 2025 the Exact Sciences (EXAS) team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients. As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Faces Shareholder Lawsuits Over Abbott Merger
- Exact Sciences ‘applauds’ passage of MCED legislation
- Abbott says ‘making great progress’ towards closing Exact Sciences deal
- ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth
- Abbott still sees Exact Sciences acquisition closing in Q2